 F2G Ltd Announces Key Appointment
Wednesday 19th April, 2006
Manchester, England, 18th April 2006 – F2G Limited, specialists in research and development of new treatments for serious fungal infections in man, is pleased to announce the appointment of Dr Lloyd Payne as Vice President of Research and Development.
Dr Payne was previously a senior scientist at Millennium Pharmaceuticals where he was responsible for the leadership of multidisciplinary drug discovery project teams based in the UK and the US. Lloyd provided direction for a number of medicinal chemistry programs from early hit validation to late stage lead optimisation and has led several successful projects focused on the development of therapies for inflammatory disorders and cancer. One such program has since delivered a novel, orally administered small molecule therapeutic into the clinic.
Lloyd has also held senior scientific and management positions within Cambridge Discovery Chemistry Ltd and NCE Discovery Ltd where he was responsible for a number of collaborative medicinal chemistry projects working with organisations across Europe, Japan and the U.S.
Lloyds experience will be invaluable as F2Gs projects move toward the clinic.
Shane Kelly, Chief Executive of F2G commented “We are delighted to welcome Lloyd to our world-class team. He has the technical and leadership skills that will accelerate the development of our programs and bring new anti fungal drugs through the clinic and onto the market. He is an outstanding addition to our scientific team.”
F2Gs technologies focus on the development of new and innovative drug treatments for systemic fungal infections in man. This market is currently estimated at over five and a half billion dollars annually and is growing at approximately 20% per year. In addition, there is new evidence suggesting a correlation between fungal infections and allergic conditions (including asthma). If proven, this would add significantly to the growth of the total addressable market. F2G has developed unique capabilities in the field including proprietary genomic targets, target validation, drug discovery and drug development. They have also amassed unique expertise in the fields of clinical need and corporate and business development specific to the field.
For more information visit www.f2g.com
Contact:
Shane Kelly
Chief Executive Officer
F2G Ltd
Tel: (+44) 0161 785 1270
Fax: (+44) 0161 785 1273
Email: [email protected]
Back to News
| 
